383 related articles for article (PubMed ID: 8491152)
1. Human growth hormone and human aging.
Corpas E; Harman SM; Blackman MR
Endocr Rev; 1993 Feb; 14(1):20-39. PubMed ID: 8491152
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
[TBL] [Abstract][Full Text] [Related]
3. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
4. [Growth hormone therapy in adults].
Góth M; Szabolcs I; Péter F
Orv Hetil; 1995 Jun; 136(23):1243-7. PubMed ID: 7784045
[TBL] [Abstract][Full Text] [Related]
5. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor I.
Wilson ME
J Clin Endocrinol Metab; 1998 Jun; 83(6):2018-28. PubMed ID: 9626134
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1.
Thum T; Hoeber S; Froese S; Klink I; Stichtenoth DO; Galuppo P; Jakob M; Tsikas D; Anker SD; Poole-Wilson PA; Borlak J; Ertl G; Bauersachs J
Circ Res; 2007 Feb; 100(3):434-43. PubMed ID: 17234973
[TBL] [Abstract][Full Text] [Related]
9. Is the somatopause an indication for growth hormone replacement?
Savine R; Sönksen PH
J Endocrinol Invest; 1999; 22(5 Suppl):142-9. PubMed ID: 10442584
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.
Thorner MO; Chapman IM; Gaylinn BD; Pezzoli SS; Hartman ML
Recent Prog Horm Res; 1997; 52():215-44; discussion 244-6. PubMed ID: 9238854
[TBL] [Abstract][Full Text] [Related]
11. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
Morales AJ; Nolan JJ; Nelson JC; Yen SS
J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
[TBL] [Abstract][Full Text] [Related]
12. Human aging and the GH-IGF-I axis.
Ghigo E; Arvat E; Gianotti L; Ramunni J; DiVito L; Maccagno B; Grottoli S; Camanni F
J Pediatr Endocrinol Metab; 1996 Jun; 9 Suppl 3():271-8. PubMed ID: 8887170
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
Benbassat CA; Maki KC; Unterman TG
J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
[TBL] [Abstract][Full Text] [Related]
15. A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I.
Sjögren K; Jansson JO; Isaksson OG; Ohlsson C
Minerva Endocrinol; 2002 Dec; 27(4):299-311. PubMed ID: 12511852
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men.
Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
J Clin Endocrinol Metab; 1993 Jan; 76(1):134-8. PubMed ID: 8421077
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
[TBL] [Abstract][Full Text] [Related]
18. Regulation of growth hormone (GH) gene expression and secretion during pregnancy and lactation in the rat: role of insulin-like growth factor-I, somatostatin, and GH-releasing hormone.
Escalada J; Sánchez-Franco F; Velasco B; Cacicedo L
Endocrinology; 1997 Aug; 138(8):3435-43. PubMed ID: 9231798
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
20. Anterior pituitary function and growth hormone use in the elderly.
Shetty KR; Duthie EH
Endocrinol Metab Clin North Am; 1995 Jun; 24(2):213-31. PubMed ID: 7656889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
